- Home
- FORA vs IBIO Comparison
FORA vs IBIO Comparison
Compare FORA & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | IBIO |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 72.2M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | FORA | IBIO |
|---|---|---|
| Price | $2.16 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 39.5K | ★ 871.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.00 | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,256,919.00 | N/A |
| Revenue This Year | $8.44 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.13 | N/A |
| 52 Week Low | $1.64 | $0.56 |
| 52 Week High | $2.71 | $3.82 |
Technical Indicators
Market Signals| Indicator | FORA | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 41.88 |
| Support Level | $2.11 | $1.43 |
| Resistance Level | $2.20 | $1.81 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.33 | 34.00 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.